242 related articles for article (PubMed ID: 31741023)
1. Proton pump inhibitors and fracture risk. The HUNT study, Norway.
Hoff M; Skovlund E; Skurtveit S; Meyer HE; Langhammer A; Søgaard AJ; Syversen U; Forsmo S; Abrahamsen B; Schei B
Osteoporos Int; 2020 Jan; 31(1):109-118. PubMed ID: 31741023
[TBL] [Abstract][Full Text] [Related]
2. Does treatment with bisphosphonates protect against fractures in real life? The HUNT study, Norway.
Hoff M; Skovlund E; Meyer HE; Langhammer A; Søgaard AJ; Syversen U; Holvik K; Abrahamsen B; Schei B
Osteoporos Int; 2021 Jul; 32(7):1395-1404. PubMed ID: 33479844
[TBL] [Abstract][Full Text] [Related]
3. Validation of FRAX and the impact of self-reported falls among elderly in a general population: the HUNT study, Norway.
Hoff M; Meyer HE; Skurtveit S; Langhammer A; Søgaard AJ; Syversen U; Dhainaut A; Skovlund E; Abrahamsen B; Schei B
Osteoporos Int; 2017 Oct; 28(10):2935-2944. PubMed ID: 28668994
[TBL] [Abstract][Full Text] [Related]
4. Anti-osteoporosis drug use: too little, too much, or just right? The HUNT study, Norway.
Hoff M; Skurtveit S; Meyer HE; Langhammer A; Søgaard AJ; Syversen U; Skovlund E; Abrahamsen B; Forsmo S; Schei B
Osteoporos Int; 2018 Aug; 29(8):1875-1885. PubMed ID: 29774403
[TBL] [Abstract][Full Text] [Related]
5. Association between proton pump inhibitors use and risk of hip fracture: A general population-based cohort study.
Wei J; Chan AT; Zeng C; Bai X; Lu N; Lei G; Zhang Y
Bone; 2020 Oct; 139():115502. PubMed ID: 32593677
[TBL] [Abstract][Full Text] [Related]
6. Use of anti-osteoporotic drugs in central Norway after a forearm fracture.
Hoff M; Skurtveit S; Meyer HE; Langhammer A; Søgaard AJ; Syversen U; Abrahamsen B; Schei B
Arch Osteoporos; 2015; 10():235. PubMed ID: 26334427
[TBL] [Abstract][Full Text] [Related]
7. Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study.
Abtahi S; Driessen JHM; Burden AM; Souverein PC; van den Bergh JP; van Staa TP; Boonen A; de Vries F
Ann Rheum Dis; 2021 Apr; 80(4):423-431. PubMed ID: 33310727
[TBL] [Abstract][Full Text] [Related]
8. Proton pump inhibitor use and the risk of osteoporosis and fracture in stroke patients: a population-based cohort study.
Lin SM; Yang SH; Liang CC; Huang HK
Osteoporos Int; 2018 Jan; 29(1):153-162. PubMed ID: 29032384
[TBL] [Abstract][Full Text] [Related]
9. Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies.
Poly TN; Islam MM; Yang HC; Wu CC; Li YJ
Osteoporos Int; 2019 Jan; 30(1):103-114. PubMed ID: 30539272
[TBL] [Abstract][Full Text] [Related]
10. Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study.
Khalili H; Huang ES; Jacobson BC; Camargo CA; Feskanich D; Chan AT
BMJ; 2012 Jan; 344():e372. PubMed ID: 22294756
[TBL] [Abstract][Full Text] [Related]
11. Use of proton pump inhibitors and mortality after hip fracture in a nationwide study.
Brozek W; Reichardt B; Zwerina J; Dimai HP; Klaushofer K; Zwettler E
Osteoporos Int; 2017 May; 28(5):1587-1595. PubMed ID: 28083667
[TBL] [Abstract][Full Text] [Related]
12. Long-term proton pump inhibitor use and risk of osteoporosis and hip fractures: A nationwide population-based and multicenter cohort study using a common data model.
Park DH; Seo SI; Lee KJ; Kim J; Kim Y; Seo WW; Lee HS; Shin WG; Yoo JJ
J Gastroenterol Hepatol; 2022 Aug; 37(8):1534-1543. PubMed ID: 35501296
[TBL] [Abstract][Full Text] [Related]
13. A population-based case-control study: proton pump inhibition and risk of hip fracture by use of bisphosphonate.
Lee J; Youn K; Choi NK; Lee JH; Kang D; Song HJ; Park BJ
J Gastroenterol; 2013 Sep; 48(9):1016-22. PubMed ID: 23307040
[TBL] [Abstract][Full Text] [Related]
14. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative.
Gray SL; LaCroix AZ; Larson J; Robbins J; Cauley JA; Manson JE; Chen Z
Arch Intern Med; 2010 May; 170(9):765-71. PubMed ID: 20458083
[TBL] [Abstract][Full Text] [Related]
15. Time-varying exposure to anti-osteoporosis drugs and risk of first-time hip fracture: a population wide study within the Norwegian Epidemiologic Osteoporosis Studies (NOREPOS).
Riska BSL; Gunnes N; Stigum H; Finnes TE; Meyer HE; Omsland TK; Holvik K
Osteoporos Int; 2023 Aug; 34(8):1369-1379. PubMed ID: 37100950
[TBL] [Abstract][Full Text] [Related]
16. Psoriasis, fracture risk and bone mineral density: the HUNT Study, Norway.
Modalsli EH; Åsvold BO; Romundstad PR; Langhammer A; Hoff M; Forsmo S; Naldi L; Saunes M
Br J Dermatol; 2017 May; 176(5):1162-1169. PubMed ID: 27718508
[TBL] [Abstract][Full Text] [Related]
17. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients.
Corley DA; Kubo A; Zhao W; Quesenberry C
Gastroenterology; 2010 Jul; 139(1):93-101. PubMed ID: 20353792
[TBL] [Abstract][Full Text] [Related]
18. Proton pump inhibitor use and the antifracture efficacy of alendronate.
Abrahamsen B; Eiken P; Eastell R
Arch Intern Med; 2011 Jun; 171(11):998-1004. PubMed ID: 21321287
[TBL] [Abstract][Full Text] [Related]
19. Increased Risk of Bone Fractures in Hemodialysis Patients Treated with Proton Pump Inhibitors in Real World: Results from the Dialysis Outcomes and Practice Patterns Study (DOPPS).
Fusaro M; D'Arrigo G; Pitino A; Iervasi G; Tentori F; Robinson B; Aghi A; Bieber B; Mccullogh K; Fabris F; Plebani M; Giannini S; Gallieni M; Tripepi G
J Bone Miner Res; 2019 Dec; 34(12):2238-2245. PubMed ID: 31365145
[TBL] [Abstract][Full Text] [Related]
20. The effect of dose and type of proton pump inhibitor use on risk of fractures and osteoporosis treatment in older Australian women: A prospective cohort study.
van der Hoorn MMC; Tett SE; de Vries OJ; Dobson AJ; Peeters GMEEG
Bone; 2015 Dec; 81():675-682. PubMed ID: 26319499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
